 | • レポートコード：MRC2012A1962 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、癌治療用チェックポイント阻害剤の世界市場を広く調査・分析し、今後の市場展望をまとめております。癌治療用チェックポイント阻害剤の種類別市場規模（PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤）、用途別市場規模（黒色腫治療、膀胱がん治療、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Bristol-Myers Squibb(BMS)、Merck、Roche、 ・地域別グローバル市場分析 2015年-2020年 ・癌治療用チェックポイント阻害剤の北米市場（アメリカ、カナダ、メキシコ） ・癌治療用チェックポイント阻害剤のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・癌治療用チェックポイント阻害剤のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・癌治療用チェックポイント阻害剤の南米市場（ブラジル、アルゼンチン） ・癌治療用チェックポイント阻害剤の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤 ・用途別分析：黒色腫治療、膀胱がん治療、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The Checkpoint Inhibitors for Treating Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Checkpoint Inhibitors for Treating Cancer market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 24.5%% in the forecast period of 2020 to 2025 and will expected to reach USD 18670 million by 2025, from USD 7770.5 million in 2019.
Market segmentation
Checkpoint Inhibitors for Treating Cancer market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Checkpoint Inhibitors for Treating Cancer market has been segmented into
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
By Application, Checkpoint Inhibitors for Treating Cancer has been segmented into:
Melanoma Treatment
Bladder Cancer Treatment
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Checkpoint Inhibitors for Treating Cancer market presented in the report. This section sheds light on the sales growth of different regional and country-level Checkpoint Inhibitors for Treating Cancer markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Checkpoint Inhibitors for Treating Cancer market.
The report offers in-depth assessment of the growth and other aspects of the Checkpoint Inhibitors for Treating Cancer market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Checkpoint Inhibitors for Treating Cancer Market Share Analysis
Checkpoint Inhibitors for Treating Cancer competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Checkpoint Inhibitors for Treating Cancer sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Checkpoint Inhibitors for Treating Cancer sales, revenue and market share for each player covered in this report.
The major players covered in Checkpoint Inhibitors for Treating Cancer are:
Bristol-Myers Squibb(BMS)
Merck
Roche
Among other players domestic and global, Checkpoint Inhibitors for Treating Cancer market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Checkpoint Inhibitors for Treating Cancer product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Checkpoint Inhibitors for Treating Cancer, with price, sales, revenue and global market share of Checkpoint Inhibitors for Treating Cancer in 2018 and 2019.
Chapter 3, the Checkpoint Inhibitors for Treating Cancer competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Checkpoint Inhibitors for Treating Cancer breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Checkpoint Inhibitors for Treating Cancer market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Checkpoint Inhibitors for Treating Cancer sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Checkpoint Inhibitors for Treating Cancer Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Market Analysis by Application
1.3.1 Overview: Global Checkpoint Inhibitors for Treating Cancer Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Overview of Global Checkpoint Inhibitors for Treating Cancer Market
1.4.1 Global Checkpoint Inhibitors for Treating Cancer Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb(BMS)
2.1.1 Bristol-Myers Squibb(BMS) Details
2.1.2 Bristol-Myers Squibb(BMS) Major Business
2.1.3 Bristol-Myers Squibb(BMS) SWOT Analysis
2.1.4 Bristol-Myers Squibb(BMS) Product and Services
2.1.5 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck SWOT Analysis
2.2.4 Merck Product and Services
2.2.5 Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche SWOT Analysis
2.3.4 Roche Product and Services
2.3.5 Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2019
3.3.2 Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Regions
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Regions (2015-2020)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Regions (2015-2020)
4.2 North America Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
4.3 Europe Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
4.5 South America Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
5.1.1 North America Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2015-2020)
5.1.2 North America Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2015-2020)
5.2 United States Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
5.3 Canada Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
5.4 Mexico Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
6.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2015-2020)
6.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2015-2020)
6.2 Germany Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
6.3 UK Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
6.4 France Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
6.5 Russia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
6.6 Italy Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Regions (2015-2020)
7.2 China Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
7.3 Japan Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
7.4 Korea Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
7.5 India Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
7.7 Australia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
8.1.1 South America Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2015-2020)
8.1.2 South America Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2015-2020)
8.2 Brazil Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
8.3 Argentina Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
9.3 Turkey Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
9.4 Egypt Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
9.5 South Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type (2015-2020)
10.2 Global Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2015-2020)
10.3 Global Checkpoint Inhibitors for Treating Cancer Price by Type (2015-2020)
11 Global Checkpoint Inhibitors for Treating Cancer Market Segment by Application
11.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2015-2020)
11.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2015-2020)
11.3 Global Checkpoint Inhibitors for Treating Cancer Price by Application (2015-2020)
12 Market Forecast
12.1 Global Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate (2021-2025)
12.2 Checkpoint Inhibitors for Treating Cancer Market Forecast by Regions (2021-2025)
12.2.1 North America Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025)
12.2.2 Europe Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025)
12.2.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025)
12.2.4 South America Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025)
12.2.5 Middle East & Africa Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025)
12.3 Checkpoint Inhibitors for Treating Cancer Market Forecast by Type (2021-2025)
12.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2021-2025)
12.3.2 Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Type (2021-2025)
12.4 Checkpoint Inhibitors for Treating Cancer Market Forecast by Application (2021-2025)
12.4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2021-2025)
12.4.2 Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Checkpoint Inhibitors for Treating Cancer Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Checkpoint Inhibitors for Treating Cancer Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Checkpoint Inhibitors for Treating Cancer Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. Bristol-Myers Squibb(BMS) Basic Information, Manufacturing Base and Competitors
Table 9. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Major Business
Table 10. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Total Revenue (USD Million) (2018-2019)
Table 11. Bristol-Myers Squibb(BMS) SWOT Analysis
Table 12. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product and Services
Table 13. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. Merck Basic Information, Manufacturing Base and Competitors
Table 15. Merck Checkpoint Inhibitors for Treating Cancer Major Business
Table 16. Merck Checkpoint Inhibitors for Treating Cancer Total Revenue (USD Million) (2018-2019)
Table 17. Merck SWOT Analysis
Table 18. Merck Checkpoint Inhibitors for Treating Cancer Product and Services
Table 19. Merck Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Roche Basic Information, Manufacturing Base and Competitors
Table 21. Roche Checkpoint Inhibitors for Treating Cancer Major Business
Table 22. Roche Checkpoint Inhibitors for Treating Cancer Total Revenue (USD Million) (2018-2019)
Table 23. Roche SWOT Analysis
Table 24. Roche Checkpoint Inhibitors for Treating Cancer Product and Services
Table 25. Roche Checkpoint Inhibitors for Treating Cancer Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2018-2019) (g)
Table 27. Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2018-2019) (USD Million)
Table 28. Global Checkpoint Inhibitors for Treating Cancer Sales by Regions (2015-2020) (g)
Table 29. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Regions (2015-2020)
Table 30. Global Checkpoint Inhibitors for Treating Cancer Revenue by Regions (2015-2020) (USD Million)
Table 31. North America Checkpoint Inhibitors for Treating Cancer Sales by Countries (2015-2020) (g)
Table 32. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2015-2020)
Table 33. North America Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2015-2020) (USD Million)
Table 34. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2015-2020)
Table 35. Europe Checkpoint Inhibitors for Treating Cancer Sales by Countries (2015-2020) (g)
Table 36. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2015-2020)
Table 37. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2015-2020) (USD Million)
Table 38. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Regions (2015-2020) (g)
Table 39. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Regions (2015-2020)
Table 40. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Regions (2015-2020) (USD Million)
Table 41. South America Checkpoint Inhibitors for Treating Cancer Sales by Countries (2015-2020) (g)
Table 42. South America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2015-2020)
Table 43. South America Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2015-2020) (USD Million)
Table 44. South America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2015-2020)
Table 45. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales by Countries (2015-2020) (g)
Table 46. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2015-2020)
Table 47. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2015-2020) (USD Million)
Table 48. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2015-2020)
Table 49. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2015-2020) (g)
Table 50. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2015-2020)
Table 51. Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2015-2020) (USD Million)
Table 52. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2015-2020)
Table 53. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2015-2020) (g)
Table 54. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2015-2020)
Table 55. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Regions (2021-2025) (g)
Table 56. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Regions (2021-2025)
Table 57. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2021-2025) (g)
Table 58. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Type (2021-2025)
Table 59. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2021-2025)
Table 60. Global Checkpoint Inhibitors for Treating Cancer Market Share Forecast by Application (2021-2025)
Table 61. Direct Channel Pros & Cons
Table 62. Indirect Channel Pros & Cons
Table 63. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Checkpoint Inhibitors for Treating Cancer Picture
Figure 2. Global Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Type in 2019
Figure 3. PD-1 Inhibitors Picture
Figure 4. PD-L1 Inhibitors Picture
Figure 5. CTLA-4 Inhibitors Picture
Figure 6. Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2019
Figure 7. Melanoma Treatment Picture
Figure 8. Bladder Cancer Treatment Picture
Figure 9. Other Picture
Figure 10. Global Checkpoint Inhibitors for Treating Cancer Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Checkpoint Inhibitors for Treating Cancer Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer in 2019
Figure 31. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Checkpoint Inhibitors for Treating Cancer Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Checkpoint Inhibitors for Treating Cancer Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 36. Global Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Regions (2015-2020)
Figure 38. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Regions in 2018
Figure 39. North America Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
Figure 40. Europe Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
Figure 42. South America Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020)
Figure 44. North America Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2015-2020)
Figure 46. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2018
Figure 47. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2018
Figure 49. United States Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 50. Canada Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 51. Mexico Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 52. Europe Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2019
Figure 55. Germany Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 56. UK Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 57. France Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 58. Russia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 59. Italy Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 60. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Regions 2019
Figure 63. China Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 64. Japan Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 65. Korea Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 66. India Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 67. Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 68. South America Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2019
Figure 70. South America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2019
Figure 71. Brazil Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 72. Argentina Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 73. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 78. Egypt Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 79. Turkey Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 80. South Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2015-2020) (g)
Figure 81. Global Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2021-2025) (g)
Figure 82. Global Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025) (g)
Figure 84. Europe Sales Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025) (g)
Figure 85. Asia-Pacific Sales Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025) (g)
Figure 86. South America Sales Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025) (g)
Figure 87. Middle East & Africa Sales Checkpoint Inhibitors for Treating Cancer Market Forecast (2021-2025) (g)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
免疫チェックポイント阻害剤の世界市場（～2026年） Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and path…- 癌チューブリン阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Cancer Tubulin Inhibitors Market The global Cancer Tubulin Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer Tubulin Inhibitors Scope and Market Size Cancer Tubulin …
- 癌治療用mTOR阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Cancer mTOR Inhibitors Market The global Cancer mTOR Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer mTOR Inhibitors Scope and Market Size Cancer mTOR Inhibitors m…
- 癌血管新生阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Cancer Angiogenesis Inhibitors Market The global Cancer Angiogenesis Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer Angiogenesis Inhibitors Scope and Market Size …
- 癌治療用ヤヌスキナーゼ阻害剤の世界市場（～2026年） Cancer Janus Kinase Inhibitors The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revol…